Pear Therapeutics, Inc. announced the publication of results from a real-world observational analysis of engagement, retention and substance use among patients with substance use disorder (SUD) treated with reSET®, the first and only FDA-authorized PDT for the treatment of SUD (including alcohol, cannabis, cocaine, and stimulants like methamphetamines). The real-world data, which demonstrated high rates of engagement, retention and abstinence from substances with reSET treatment through 12 weeks, was published in The American Journal on Addictions(AJA). The real-world observational analysis was conducted in an all-comer population of 602 patients with SUD treated with reSET over 12 weeks.

Substance use was evaluated as a composite of self-reports and urine screens. Summary of results: Over 74% of patients were retained in reSET treatment and continued to use their PDT during the last four weeks (weeks 9-12); Abstinence rates during the last four weeks were 62% where missing data was treated as a positive urine screen (n=602) and 86% where the missing data was excluded from the analysis (n=434); Of the patients using reSET appropriately (four or more lessons per week on average for the first four weeks) (n=258), 81% were abstinent and 92% were retained at 12 weeks. Pear's products reSET and reSET-O for the treatment of SUD and opioid use disorder (OUD), respectively, have been measured in real-world use and their therapeutic content studied in randomized controlled trials, with results published in peer-reviewed medical journals.3,4 Pear recently released publications showing the potential for improved real-world health outcomes and decreased healthcare resource utilization for patients using reSET and reSET-O.5-17 Both products, which are adjunctive to outpatient care, provide patients with cognitive behavioral therapy, fluency training, and contingency management, while clinicians receive access to clinical dashboards to inform in-office and televisits.